Summary
Normal, coumarin, factor II deficient, factor VII deficient, factor X deficient, factor IX deficient, abnormal factor IX and abnormal factor X (factor X Friuli) plasmas were diluted 1∶1, 1∶2, 1∶3, 1∶5 and 1∶10. Variable aliquots of such dilutions were then added to several tissue thromboplastins and the clotting time measured. Four thromboplastin reagents were used: Thrombotest, Normotest, Manchester Thromboplastin and Simplastin A. Using Manchester Thromboplastin absorbed normal plasma was added to the system too.
The “inhibitory effect” present in the system was evaluated by means of conventional units “i”.
Using Thrombotest, Manchester Thromboplastin or Simplastin A a variable but clear “inhibition” (“i”>0.5 units) was found in all plasmas. Using Normotest a slight “inhibition” was present only in coumarin plasmas and in factor VII or factor X deficient plasmas.
In factor IX deficient plasma no inhibition could be assessed since in all cases it gave a dilution curve identical to the normal plasma one.
The studies indicate that the dilution curve analysis has no value in the case of single congenital prothrombin factors deficiencies since these plasmas “behave” in the system in a way similar to coumarin plasma.
Zusammenfassung
Normalplasma und Cumarinplasma, ferner die Mangelplasmen von Faktor II, VII, X, IX sowie abnormales Faktor IX- und abnormales Faktor X- (Faktor X Friuli)-Plasma wurden 1∶1, 1∶2, 1∶3, 1∶5 und 1∶10 verdünnt. Wechselnde Aliquote dieser Verdünnungen wurden verschiedenen Gewebsthromboplastinen zugegeben und die Gerinnungszeiten bestimmt.
Vier Thromboplastin-Reagenzien kamen zur Verwendung: Thrombotest, Normotest, Manchester-Thromboplastin und Simplastin A.
Der Hemmeffekt wurde in Einheiten “i”ausgedrückt, die Gerinnungszeiten in Verdünnungskurven dargestellt und deren Bedeutung diskutiert.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bangham, D. R., R. Biggs, M. Brozovic and K. W. E. Denson: Draft report of a collaborative study of two thromboplastins (including the use of common abnormal plasma), Thromb. Diath. Haem. Suppl.40, 341 (1970).
Denson, K.W.: Levels of blood-coagulation factors during anticoagulant therapy with phenindione. Brit. Med. J.1, 1205 (1961).
Dixon, M. and E. C. Webb: Enzymes. Sec. Ed., pag. 54–166, Longmans Co., London 1964.
Girolami, A., G. Molaro, M. Lazzarin, R. Scarpa and A. Brunetti: A “new” congenital hemorrhagic condition due to the presence of an abnormal factor X (factor X Friuli). Study of a large kindred. Brit. J. Haemat.19, 179 (1970).
Girolami, A.: The hereditary transmission of true congenital hypoprothrombinemia. Brit. J. Haemat.21, 695 (1971).
Girolami, A., M. Lazzarin and G. Molaro: The effect of several tissue thromboplastins on the activation of the abnormal factor X (factor X Friuli). Thromb. Diath. Haem.27, 535 (1972).
Girolami, A., G. Cella and G. Bareggi: Hemophilia B+ or BM. First case reported in Italy. Blut26, 268 (1973).
Girolami, A., A. D. Muller and H. C. Hemker: Lack of PIVKA effect in the abnormal factor X (factor X Friuli) coagulation disorder. Haemostasis I, 23 (1972).
Girolami, A., G. Cattarozzi, G. Mengarda and M. Lazzarin: Congenital factor VII deficiency. A case report. Blut27, 236 (1973).
Hemker, H. C., J. J. Veltkamp and E. A. Loeliger: Kinetic aspects of the interaction of blood clotting enzymes. III. Demonstration of an inhibitor of prothrombin conversion in vitamin K deficiency. Thromb. Diath. Haem.19, 346 (1968).
Hemker, H. C. and P. W. Hemker: Kinetics aspects of the interaction of blood clotting enzymes. IV. Kinetics of comparative inhibition in clotting tests. Thromb. Diath. Haem.19, 364 (1968).
Hemker, H. C.: The thrombotest dilution curve and its diagnostic significance. In: Human blood coagulation. Hemker, H. C., Loeliger E. A., Veltkamp, J. J. (Editors), pag. 365–368, Leiden, University Press 1969.
Josso, F., J. Monasterio de Sanchez, J. M. Lavergne, D. Ménaché and J. P. Soulier: Congenital abnormality of the prothrombin molecule (factor II) in four siblings: prothrombin Barcelona. Blood38, 10 (1971).
Korsan-Bengtsen, K.: Comparison between various methods used to control dicumarol therapy. Acta Med. scand.188, 327 (1970).
Lineweaver, H. and D. Burk: The determination of enzyme association constants. J. Amer. Chem. Soc.56, 658 (1934).
Loeliger, E. A., J. Meuwisse-Braun, H. Muis, F. J. J. Buitendijk, J. J. Veltkamp and H. C. Hemker: Laboratory control of oral anticoagulant. Definition of therapeutic range in terms of different thromboplastin preparations. Thromb. Diath. Haem.23, 569 (1970).
Miale, J. B. and D. J. La Fond: Prothrombin time standardization. Am. J. Clin. Path.52, 154 (1969).
Miale, J. B. and J. W. Kent: Standardization of the therapeutic range for oral anticoagulants based on standard reference plasmas. Am. J. Clin. Path.57, 80–88 (1971).
Owren, P. A.: Thrombotest. A new method for controlling anticoagulant therapy. Lancet2, 754 (1959).
Owren, P. A.: The interrelationship between Normotest and Thrombotest. Farmakoterapi25, 1 (1969).
Poller, L.: Anticoagulant therapy standards: results of two national surveys. Thromb. Diath. Haem. Suppl.35, 115 (1969).
Rodman, Th. and B. H. Pastor: Control of anticoagulant therapy with the Thrombotest. Am. J. Med. Ass.180, 739 (1962).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Girolami, A., Brunetti, A., De Marco, L. et al. Dilution curve studies in prothrombin complex factors deficiencies and abnormalities. Blut 29, 134–143 (1974). https://doi.org/10.1007/BF01633837
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01633837